RxDoctor Payments Data

Meredith Alford, PA

Medical · San Marcos, TXNPI 1932659257

Payments from drug & device makers

$3,153in general payments, 2019–2025

Across 161 payments — averaging $19.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$713
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$432
  • Abbott$399
  • Johnson & Johnson$259
  • Amgen$231
  • Boston Scientific$166
  • plus $953 from 22 others

What the payments were for

  • Food & beverage$3,153100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,153 in reported general payments places this provider in the 75th percentile of 1,490 medical providers in Texas.

See all medical providers in Texas

Medicare billing

Part B allowed, 2024
$8,798
Medicare patients
67
Services billed
92

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban126$116,918
FuroscixFurosemide14$92,841
XareltoRivaroxaban31$38,934
Repatha SureclickEvolocumab26$28,170
EntrestoSacubitril/Valsartan22$25,765
MultaqDronedarone Hcl19$10,933
Clonidine47$3,705
Ezetimibe115$2,579
Potassium Chloride150$2,231
Carvedilol281$2,149
Ranolazine ErRanolazine42$1,888
Rosuvastatin Calcium138$1,855
Dabigatran EtexilateDabigatran Etexilate Mesylate11$1,747
Atorvastatin Calcium204$1,617
Torsemide69$1,584

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$81$116,918126 claims
Scpharmaceuticals Inc.Furoscix$14$92,84114 claims
Johnson & JohnsonXarelto$259$38,93431 claims
NovartisEntresto$713$25,76522 claims
Sanofi-aventis U.S. LLCMultaq$42$10,93319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,490 medical providers in Texas.

Other medical in San Marcos

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →